Skip to main content
VXRT
OTC Life Sciences

Vaxart Faces Proxy Contest as Dissident Shareholder Nominates Rival Board Slate

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.61
Mkt Cap
$147.604M
52W Low
$0.261
52W High
$0.845
Market data snapshot near publication time

summarizeSummary

Vaxart has filed its preliminary proxy statement, revealing a proxy contest initiated by a shareholder group seeking to replace board members at the upcoming 2026 Annual Meeting. The company's board is urging shareholders to vote for its recommended nominees and against the dissident slate.


check_boxKey Events

  • Proxy Contest Initiated

    A shareholder group led by Daniel P. Houle has nominated three candidates for election to the Board of Directors at the 2026 Annual Meeting, opposing the company's recommended nominees.

  • Board Rejects Dissident Nominees

    Vaxart's Board of Directors unanimously recommends voting 'FOR' its six proposed nominees and 'NOT' for the three candidates put forth by the Houle Group, citing their lack of relevant industry experience.

  • Shareholder Activism Continues

    This proxy contest follows a history of shareholder opposition, including the failure to approve a reverse stock split in 2025, which led to the company's delisting from Nasdaq.

  • Dissident Group Holdings

    The Houle Group collectively owned approximately 0.7% of Vaxart's outstanding common stock as of February 20, 2026.


auto_awesomeAnalysis

This preliminary proxy statement formally details Vaxart's position in a significant proxy contest. A dissident shareholder group, led by Daniel P. Houle, is challenging the current board by nominating three alternative candidates for election. The Board has unanimously rejected these nominees, citing a lack of relevant industry experience, and is actively urging shareholders to vote for its own slate. This event is particularly critical given Vaxart's recent history of shareholder activism, including the failure to pass a reverse stock split in 2025 which resulted in Nasdaq delisting. The outcome of this contest could lead to substantial changes in corporate governance and potentially influence the company's strategic direction, especially following its recent financial turnaround and alleviation of its going concern warning.

At the time of this filing, VXRT was trading at $0.61 on OTC in the Life Sciences sector, with a market capitalization of approximately $147.6M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed VXRT - Latest Insights

VXRT
May 20, 2026, 7:24 AM EDT
Filing Type: DEFA14A
Importance Score:
8
VXRT
May 19, 2026, 5:25 PM EDT
Filing Type: PREC14A
Importance Score:
9
VXRT
May 19, 2026, 5:19 PM EDT
Filing Type: DEFA14A
Importance Score:
8
VXRT
May 19, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
VXRT
May 19, 2026, 4:55 PM EDT
Filing Type: DEFA14A
Importance Score:
8
VXRT
May 19, 2026, 4:30 PM EDT
Filing Type: 424B3
Importance Score:
8
VXRT
May 08, 2026, 5:30 PM EDT
Filing Type: S-1
Importance Score:
8
VXRT
May 07, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
9
VXRT
May 07, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
VXRT
May 04, 2026, 5:29 PM EDT
Filing Type: 424B5
Importance Score:
9